Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms.
BACKGROUND
Pharmacogenetic testing for drug-metabolizing enzymes is not yet widely used in clinical practice.


METHODS
In an attempt to facilitate the application of this procedure, we have compared two real-time PCR-based methods, the TaqMan and the LightCycler for the pharmacogenetic evaluation of CYP2C9*2/*3 polymorphisms.


CONCLUSIONS
Both procedures are suitable for pharmacogenetic studies. The TaqMan procedure was less expensive in terms of cost per sample, but the TaqMan apparatus is more expensive than the LightCycler apparatus.
Toriello
Mario
M
CEINGE-Biotecnologie Avanzate S.C.a r.l., Naples, Italy.
Meccariello
Pasquale
P
Mazzaccara
Cristina
C
Di Fiore
Rosanna
R
Esposito
Carmela
C
Sacchetti
Lucia
L
D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism*; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D010597:Pharmacogenetics / Q000191:economics / Q000379:methods*; D016133:Polymerase Chain Reaction / Q000379:methods; D011110:Polymorphism, Genetic; D012680:Sensitivity and Specificity; D019914:Taq Polymerase / Q000235:genetics / Q000378:metabolism*; D013696:Temperature
C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D019914:Taq Polymerase